Composition of desmodium and trivalent chromium, and ocular use
US12076358B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 23, 2020 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | Sep 11, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The composition comprises a preparation of Desmodium and a trivalent chromium salt. The composition preferably comprises Desmodium adscendens or Desmodium gangeticum and chromium chloride, chromium nicotinate or chromium picolinate. It is formulated alone or with other active substances, excipients or additives, for oral administration as a medicinal product, phytomedicinal product, medical device, dietary supplement or admixture to a food product. It is intended for use in the prevention or treatment of a retinal degenerative disease such as age-related maculopathy (ARM) and dry or wet age-related macular degeneration (ARMD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.